Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07141199
PHASE1

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.

Official title: A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-8736 After Multiple Ascending Doses in Healthy Adult Subjects

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2025-09-02

Completion Date

2026-04

Last Updated

2026-02-23

Healthy Volunteers

Yes

Interventions

DRUG

ABBV-8736

Intravenous (IV) Infusion

DRUG

Placebo

IV Infusion

Locations (1)

Acpru /Id# 277377

Grayslake, Illinois, United States